Ulipristal Acetate 99%

SWATI is a global research-oriented pharmaceutical company with a vision to take science to market. Headquartered in Mumbai, with a distinguished history spanning over five decades. Our commitment extends beyond expanding our product range, for the past twenty-five years, we have dedicated ourselves to addressing neglected diseases.

SWATI is recognised for its unwavering commitment to quality, compliance, and innovation, serving a diverse clientele across more than 70 countries. With multiple advanced API and intermediate manufacturing facilities in Vapi, Gujarat, the company fully integrates its core product lines, encompassing the entire value chain from production to finished formulations.

SWATI has achieved a global milestone by being the first to introduce a generic version of a drug that had been exclusive to the United States for over 20 years, priced at USD 25,000 per treatment.

We have introduced this generic in India and several other countries at a significantly reduced price of approximately USD 1,200—representing just 5% of the original cost. In addition, SWATI holds patents for treatments targeting kidney-related diseases, addressing critical therapeutic gaps where no existing medications are available for patients in need.